#United States #Liquid Biopsy #Hamilton #Reno #nRichDX

nRichDX and Hamilton: A Game Changer in Liquid Biopsy Preparation

In a groundbreaking collaboration, nRichDX and Hamilton have announced the integration of their advanced technologies to create a powerful automated solution for liquid biopsy sample preparation. This new system combines the nRichDX Revolution Plus™ Sample Prep System with the Hamilton Microlab STAR® liquid handling platform, setting unprecedented standards in the industry for yield, flexibility, and automation.

Automation and High-Performance Workflow

The joint solution is designed to deliver streamlined workflows that simplify the isolation of key biomolecules like circulating cell-free DNA (cfDNA), circulating cell-free RNA (cfRNA), circulating cell-free total nucleic acid (cfTNA), and circulating tumor cells (CTCs) from various biofluids such as plasma and urine. The main advantage is the minimal hands-on time required, allowing laboratories to perform high-yield extractions efficiently.

Key features of the system include:

• - Scalability: It offers automated, high-yield workflows tailored for liquid biopsy, which is crucial for both research and clinical applications.
• - Input Volume Flexibility: The technology allows users to work with input volumes ranging from just 1 mL up to 100 mL in a single extraction process, addressing a wide range of laboratory needs.
• - Walk-Away Operation: Laboratories can enjoy a walk-away operation feature that enhances operational efficiency and productivity, providing straightforward and reliable liquid biopsy workflows.

Transforming Precision Medicine

William Curtis, CEO of nRichDX, emphasized the collaborative effort's significance: “nRichDX is setting a new standard for liquid biopsy sample preparation performance and workflow efficiency. Together with Hamilton, we're enabling laboratories to achieve the highest analyte yields while benefiting from flexible, scalable automation.”

Michael Mouradian, Vice President of Scientific Strategy & Market Development at Hamilton, echoed this sentiment by stating that this collaboration advances precision medicine through robust automation technology.

Engagement and Future Developments

The new automated solution was first introduced at the Association for Molecular Pathology (AMP) Annual Meeting in 2025, where it generated significant interest among leaders in molecular diagnostics and clinical laboratory fields. The collaboration was showcased through scientific presentations and posters that demonstrated the effectiveness of their automated liquid biopsy workflows.

This introduction lays the groundwork for further joint development and expands commercial activities, indicating a promising future for both companies in advancing liquid biopsy methodologies.

About nRichDX and Hamilton

nRichDX specializes in providing advanced kits and automated solutions for isolating various nucleic acids crucial in liquid biopsy procedures. Their patented Revolution Sample Prep System™ is at the forefront of liquid biopsy technology, proving to be a reliable choice for extracting analytes from different biological fluids.

Meanwhile, Hamilton has over 75 years of experience as a leader in precision measurement devices and automated solutions. With a commitment to high-quality performance, Hamilton remains dedicated to meeting the evolving needs of laboratories worldwide.

For labs seeking to overcome challenges such as yield limitations and workflow variability in rare-analyte extraction, the integration of nRichDX and Hamilton's technologies marks a significant step forward.

For further details, visit nRichDX and Hamilton.